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Background: Even if right bundle branch block pattern or increased PR
interval duration has been earlier noted in Brugada syndrome (BS) patients,
prevalence and prognostic value of various conduction disturbances in BS
remains poorly known.
Methods: ECGs from 238 BS patients with spontaneous (n=126) or drug
induced type 1 ECG (n=112) (45±12 years old, 188 males) were reviewed.
ECG with the highest ST elevation were selected in each patient. Presence of
complete or incomplete right bundle branch block (RBBB) and of left anterior
(LAFB) or posterior (LPFB) fascicular block were evaluated according to cur-
rent guidelines for ECG interpretation. RBBB was defined by QRS > 110 or
120 ms width and S wave >40 ms in lead I. 99 patients were implanted with
an ICD. 72 patients (30%) presented an arrhythmic event defined by unex-
plained syncope (54 pts), SD (8 pts) or ICD appropriated therapies (14 pts).
Results: PR interval was 180±40 ms. 64 pts (27%) had 1st degree AV
block. AV block was not correlated to arrhythmic events but was correlated to
SCN5A mutations (66% vs 18%, p<0,0001).
62 pts (26%) had complete (56) or incomplete (6) RBBB. SCN5A muta-
tion was more often present in case of RBBB (42% vs 26%, p=0,05). ECG
with RBBB were more often recorded during pharmacological challenge (69%
vs 55%, p=0,01). Pts with RBBB had longer PR intervals (189±37 vs 174±33
ms, p=0,01). There was no correlation with HV interval, the presence of fas-
cicular blocks or degree of ST elevation.
33 pts (14%) had LAFB and 11 pts (5%) had LPFB. Fascicular blocks
were not related to PR or HV interval or RBBB. SCN5A mutation was more
often present in case of fascicular blocks (54% vs 27%, p=0,05).
There was no correlation with any arrhythmic event for the presence of
RBBB or fascicular blocks.
Conclusion: RBBB can be seen in a quarter of patients with BS, while left
anterior or posteror fascicular blocks are present in 14 and 5% respectively.
They were related to SCN5A mutations but not to arrhythmic events and could
not be used for further risk stratification.
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Diagnostic value of isoproterenol test in arrhythmogenic right ventri-
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Background: Initially proposed in 1994, the diagnosis criteria of arrhyth-
mogenic right ventricular cardiomyopathy (ARVC) have been recently
updated. However, diagnosis sensitivity remains poor at early stage of the dis-
ease or for familial screening. The aim of this study was to evaluate the diag-
nostic value of isoproterenol test in ARVC.
Methods: All patients referred to our institution for premature ventricular
contraction (PVC) evaluation had isoproterenol test (continuous infusion of
isoproterenol (45 to 65 μg/min) over 3 minutes, regardless of the heart rate).
Continuous 12 leads ECG, signal average ECG, holter ECG, exercise test,
echocardiogram and MRI were analysed. Isoproterenol test was considered
positive if (1) polymorphic PVC with at least one couplet (2) sustained or non
sustained ventricular tachycardia with left bundle branch morphology (but
RVOT) occurred during the test or within 10 minutes after the end of infusion.
All patients were contacted between may and july 2010. A new evaluation
was performed two years after the first one for those having a suspicion of
ARVC but didn't fulfil Task Force Criteria (TFC).
Results: 261 consecutive patients (137 men, aged 43+/–17 years) were
included in this study. Mean follow-up was 4,7+/–10,4 years (median 5 years).
The diagnosis of ARVC based on current TFC was present in 19 patients at
the initial work up and in 24 patients (17 men, aged 39+/–14 years) at the end
of the follow-up. Initial isoproterenol test was positive in 96% of the ARVC
patients and in 9% of the patient without ARVC (p<0,01). Isoproterenol test
was positive for all patients (n=5) that did not initially meet diagnosis criteria
for ARVC but subsequently developed patent form of ARVC. The sensitivity
of the isoproterenol test was 96% and the predictive positive value was 99,5%.
Conclusion: Isoproterenol test is highly sensitive (sensitivity 96%) for the
diagnosis of ARVC. This test may be used in addition to current TFC to
improve their sensibility.
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Background and aim: The new pacemaker (PM) generations featuring
extended memory functions (MF) document the occurrence of arrhythmias
over periods of several months. However, ventricular arrhythmia (VA) char-
acteristics and occurrences are less well-known in this pacemaker population.
The goal of this analysis was to evaluate the pertinence of MF at the ventric-
ular level and to describe the MF-documented VA.
Methods & Results: This analysis involved 700 pts (M 60%, F 40%, aged
76±10 yrs) implanted with single or dual chamber PM for AVB 55% or SD
45% who were seen in PM follow-up. 1438 visits were analyzed (follow-up
average at 13 months) over a period from 2 to 87 months after implantation.
Occurrences of VA are validated by EGMs, defined by at least 5 QRS com-
plexes >175/mn. The number of episodes and the duration and heart rate
during the longest arrhythmia episodes were recorded. 110 pts (16%) average
ages 75±8 yrs of whom 62% males, showed VA in 299 visits (21%). The
average number of episodes was 11 per follow-up (1-140), average duration
was 5±9 seconds (1-62 sec), and average rate was 210±28 bpm (175-295 bpm).
97% of episodes were classified as non-sustained ventricular tachycardia
(NSVT) and 3% like SVT (33-62 sec). The ejection fraction was 51±11%
(p<0.05) in the VA group compare to 57±11% in the non VA group. 64% of
VA pts shown cardiopathy compare to 45% in the non VA group (p<0.001).
Statistical analysis shown that age, pacing indication, pacing mode and cumu-
lated percentage of pacing are not relevant factors in NSVT and VT.
Conclusion: Ventricular arrhythmias are observed in 16% of pts implanted for
standard pacing indications. A major determining factor in the occurrence of
NSVT and VT is the presence of an associated cardiopathy. FMs featuring EGM
recordings are a tool for reliable diagnostic and monitoring of these events. Further
studies are required to evaluate the prognostic significance of these arrhythmias.
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Conscious sedation instead of general anesthesia for epicardial VT ablation
Khaled Ramoul [Orateur] (1), Nadir Tafer (2), Pierre Jais (1), Sebastien
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Because catheter manipulation and ablation in the pericardial space is
extremely painful, most of the EP centers perform epicardial VT procedure under
general anesthesia (GA). However, GA lowers blood pressure, may interfere with
arrhythmia mapping, and use of muscle relaxants precludes identification of the
phrenic nerve. Moreover, the presence in the EP lab of an anesthesiologist is man-
datory during the whole GA. We report our experience of epicardial VT ablation
performed under conscious sedation using midazolam and sufentanyl.
Methods: All patients referred between 2006 and 2010 for epicardial VT
ablation, were scheduled to have their procedure under conscious sedation in
the absence of contraindications. Analgesia protocol included first the perfu-
sion of 1 gram of paracetamol (acetaminophen) IV and 20 mg of Nefopam IV.
Then midazolam IV was injected (bolus of 0,05 mg/kg) followed by 5 micro-
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grams of sufentanyl just before epicardial access and that was repeated up to
4 times (20 μg) in case of persistent pain and absence of respiratory depres-
sion. Blood pressure and O2 saturation were continuously monitored.
Results: 74 epicardial VT ablations have been performed in 65 patients (58 M,
58±13yo), 58 (89%) had a structural heart disease with a mean LVEF of 40±15%.
69 were performed under conscious sedation using the above protocol. 5 proce-
dures were performed under GA: 4 because patients had to be sedated for
arrhythmic storm before ablation and 1because of respiratory contraindications.
Mean midazolam and sufentanyl dosages were 4±1,5 mg and 10±5 μg respec-
tively. RF ablation was performed in 57 procedures with mean epicardial RF dura-
tion of 9±11 min for a total procedure time of 243 ±90 min. Because of pericardial
bleeding 2 patients were transferred to the operating room and one patient had
developed metabolic acidosis but no patient had respiratory failure during the pro-
cedure.
Conclusion: Epicardial VT ablation can be performed safely under con-
scious sedation using powerful painkiller such as sufentanyl.
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Background: Pericardial effusion can occur during or after atrial fibrilla-
tion ablation and may induce atrial arrhythmia.
Aims: We aimed to characterize the impact of pericardial effusion on
arrhythmia recurrences following atrial fibrillation ablation.
Methods: We studied prospectively patients referred for a first atrial fibrilla-
tion ablation. We performed transthoracic echocardiography before and 24 hours
after the procedure. If pericardial effusion was present, transthoracic echocardio-
graphy was repeated at one month to evaluate pericardial effusion evolution. Early
arrhythmia recurrences were defined as any arrhythmia documented within
1 month following the procedure. Eighty-one patients were included in our study.
Results: Pericardial effusion was diagnosed in 22% of cases and was present
in 35% of patients with persistent atrial fibrillation vs. 10% for paroxysmal atrial
fibrillation (p=0.008). Pericardial effusions were mild (6±3 mm), asymptomatic
(89%) and none of them required pericardiocentesis.
Early and late arrhythmia recurrences were present in 31% and 36%
respectively in our population. The incidence of pericardial effusion was sig-
nificantly higher in patients with early arrhythmia recurrences compared to
patients without early arrhythmia recurrences (48% vs. 11%, p=0.0004). On
multivariate analysis pericardial effusion and duration in atrial fibrillation
were the two independent predictors of early arrhythmia recurrences.
Pericardial effusion incidence was similar in patients with and without late
arrhythmia recurrences. At one month none of our patients had PE on TTE.
Conclusion: Pericardial effusion following atrial fibrillation ablation is fre-
quent, particularly following persistent atrial fibrillation ablation. This effu-
sion is mild, mainly asymptomatic and independently associated with early
arrhythmia recurrences.
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Aims: We analysed outcomes of 163 patients (pts) with ICD using remote
monitoring follow-up (RFU)
Methods: 163 pts were implanted with an ICD with a Remote Patient
Management (RPM) system. 82 patients (51%) were implanted with biventric-
ular ICDs (CRT-D), 63 (39%) with dual chamber ICDs (D-ICD), and 15 (9%)
with single chamber ICDs (S-ICD). 31 CRT-D pts had also weight and blood
pressure monitoring. RFU was performed every 3 months.
Results: Mean FU with RPM system was 15±10 months. 379 episodes of sus-
tained atrial arrhythmias occured in 13 pts. 287 episodes of ventricular arrhyth-
mias required therapies: 265 (90.6%) were approprialely treated by Anti-
Tachycardia Pacing (ATP), 22 with ICD discharge,only 3 inappropriate shocks. In
the last 7 months of FU, 25 patients were examined at hospital after non-vital
alerts: oral anticoagulation(4 pts) and amiodarone(2 pts) were started, diuretics
dosage increased (5 pts),device reprogrammed in 14 patients. During FU,
5 patients had VT recurrences requiring VT ablation (2 pts),1 pt required a short
heart failure hospitalisation. Pts with S-ICD had less clinical FU in hospital. D-
ICD pts had a higher rate of RFU. In 13 CRT-D pts, alarms indicated biventricular
pacing <85%:we reprogrammed the device (2 pts), changed medical therapeutics
(5 pts), performed AV junction(5 pts) and cavo-tricuspid ablation (1 pt).
Conclusion: RPM is an effective tool for the FU of ICD pts. D-ICDs and
CRT-ICDs had more RPM alerts, and could early detect atrial arrythmias
comparing to S-ICD. RPM helps both physicians and pts for HF management
and for reducing inappropriate ICD shocks.
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Paroxysmal supraventricular tachycardia (SVT) requires a treatment in
patients with recurrent SVT’s. Some of them refuse the radical treatment of
SVT. The purpose of the study was to know the number of patients who
accept SVT ablation, the reasons and the delay between initial electrophysio-
logical study (EPS) and the time of ablation.
Methods: 1268 patients with a normal ECG in sinus rhythm were consec-
utively recruited for SVT’s, confirmed by EPS. Patients with anterograde con-
duction through an accessory pathway (AP) were excluded. Ablation
indications and the time between EPS and ablation were studied.
Results: 652 patients were directly seen for EPS and ablation, because SVT’s
were documented and recurrent (group I). SVT was induced at EPS in
481 patients, but ablation was not performed (group II). Ablation was performed
in a second time after EPS in 135 patients (group III). The mean time between
EPS and ablation was 4±5 years. Group I differs from group II and III by an older
age (53±18 vs 47±19 and 43±18.5 years, p<0.0000), the female gender more fre-
quent than in group II (64.5% vs 55%, p<0.001), but similar in group III (61%).
Syncope associated with SVT was less frequent in group I (7.5%) than in group II
(18/5%) and III (19%) (p<0.0000). The rate in tachycardia was slower in group I
(177±34 bpm) than in group II (189±38) (p<0.0005) and III (193±33) (p<0.0001).
The electrophysiological mechanism was similar in 3 groups. Reentry in a con-
cealed AP was noted in 17.5% of group I patients, 21% of group II patients and
19% of group II patients. Typical and atypical atrioventricular nodal reentrant
tachycardias represent the other causes.
Conclusions: Among patients with proved SVT at EPS, ablation of the
substrate will never be achieved in 38% of patients and will be made at least
4 years after the evaluation in 11% of patients. Only age and gender influence
the decision. Symptoms, rate and mechanism of SVT do not change the indi-
cations of ablation.
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Purpose: Increasing numbers of patients requiring arrhythmia device
implantation are treated with clopidogrel. This study aimed to assess the risk
